CenterBook Partners LP Has $3.62 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CenterBook Partners LP decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 64.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,714 shares of the biopharmaceutical company's stock after selling 10,270 shares during the period. CenterBook Partners LP's holdings in Regeneron Pharmaceuticals were worth $3,624,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Marietta Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock worth $6,836,000 after purchasing an additional 2,501 shares during the last quarter. Pamalican Asset Management Ltd acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $4,915,000. Rhenman & Partners Asset Management AB increased its position in Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock valued at $30,956,000 after acquiring an additional 4,457 shares during the period. GAMMA Investing LLC increased its position in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in Regeneron Pharmaceuticals by 3.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 4.0%

NASDAQ REGN traded down $22.63 on Tuesday, reaching $547.96. The stock had a trading volume of 998,434 shares, compared to its average volume of 918,917. The business has a 50 day moving average price of $544.56 and a 200 day moving average price of $618.18. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The company has a market capitalization of $59.16 billion, a price-to-earnings ratio of 13.95, a P/E/G ratio of 2.11 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter last year, the firm earned $9.55 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on REGN shares. Royal Bank Of Canada cut Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. Citigroup lowered their target price on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research report on Monday, June 2nd. Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research report on Monday, June 2nd. Finally, The Goldman Sachs Group lowered their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $823.54.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.